Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis.

Inflammatory bowel diseases - 12 Jul 2018

Burke Kristin E, Khalili Hamed, Garber John J, Haritunians Talin, McGovern Dermot P B, Xavier Ramnik J, Ananthakrishnan Ashwin N

Abstract excerpt

Background: Despite a high nonresponse rate, predictors of response to anti-tumor necrosis factor (anti-TNF) therapy in ulcerative colitis (UC) remain limited. We aim to determine clinical and genetic predictors of primary nonresponse (PNR) and durable response (DR) to anti-TNF therapy in a large prospective UC cohort. Methods: Using the Illumina Immunochip, candidate polymorphisms associated with clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Boston

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colitis, Ulcerative

Share to Gastrointestinal Agents

Share to Infliximab

Share to Pharmacogenomic Variants

Share to Registries

Share to ROC Curve

Source

Open in PubMed Open full text

Identifiers

PMID: 29718226
DOI: 10.1093/ibd/izy083
PMCID: PMC6128143

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis.PMID 29718226Read ↗

Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.Semantic proximity Read ↗

Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease.Semantic proximity Read ↗

Development of a Machine Learning Model to Predict Non-Durable Response to Anti-TNF Therapy in Crohn’s Disease Using Transcriptome Imputed from GenotypesSemantic proximity Read ↗

Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.Semantic proximity Read ↗

Genetic and genomic predictors of anti-TNF response.Semantic proximity Read ↗

Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.Semantic proximity Read ↗

Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.Semantic proximity Read ↗

Genetic association of primary non-response to Anti-TNFα therapy in patients with Inflammatory Bowel DiseaseSemantic proximity Read ↗

The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases.Semantic proximity Read ↗

Association of the TNFRSF1B rs1061622 variant with nonresponse to infliximab in ulcerative colitisSemantic proximity Read ↗

Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.